VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- December 04, 2006 -- Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) today announced the topline results from the US Phase II trial of its cholesterol-lowering drug, FM-VP4. Preliminary data received over the weekend confirmed the drug is dose responsive, produces a statistically significant reduction in LDL (or bad) cholesterol and has maintained an excellent safety profile. The primary endpoint of the study was met with a statistically significant reduction in LDL after 12 weeks of 9% from baseline at 900mg, however, FM-VP4 did not achieve the Company's established goal of a 15% average reduction in LDL cholesterol from baseline.
